|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Zannoni GF, Scambia G and Gallo D: The
dualistic model of endometrial cancer: the challenge of classifying
grade 3 endometrioid carcinoma. Gynecol Oncol. 127:262–263. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amant F, Moerman P, Neven P, Timmerman D,
Van LE and Vergote I: Endometrial cancer. Lancet. 366:491–505.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kamat AA, Merritt WM, Coffey D, Lin YG,
Patel PR, Broaddus R, Nugent E, Han LY, Landen CN Jr, Spannuth WA,
Lu C, Coleman RL, Gershenson DM and Sood AK: Clinical and
biological significance of vascular endothelial growth factor in
endometrial cancer. Clin Cancer Res. 13:7487–7495. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rasila KK, Burger RA, Smith H, Lee FC and
Verschraegen C: Angiogenesis in gynecological oncology-mechanism of
tumor progression and therapeutic targets. Int J Gynecol Cancer.
15:710–726. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seki N, Kodama J, Hongo A, Miyagi Y,
Yoshinouchi M and Kudo T: Vascular endothelial growth factor and
platelet-derived endothelial cell growth factor expression are
implicated in the angiogenesis of endometrial cancer. Eur J Cancer.
36:68–73. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stefansson IM, Salvesen HB and Akslen LA:
Vascular proliferation is important for clinical progress of
endometrial cancer. Cancer Res. 66:3303–3309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fischer C, Mazzone M, Jonckx B and
Carmeliet P: FLT1 and its ligands VEGFB and PlGF: drug targets for
anti-angiogenic therapy? Nat Rev Cancer. 8:942–956. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carmeliet P, Moons L, Luttun A, Vincenti
V, Compernolle V, De MM, Wu Y, Bono F, Devy L, Beck H, Scholz D,
Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A,
Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH,
Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM,
Collen D and Persico MG: Synergism between vascular endothelial
growth factor and placental growth factor contributes to
angiogenesis and plasma extravasation in pathological conditions.
Nat Med. 7:575–583. 2001. View
Article : Google Scholar
|
|
11
|
Fischer C, Jonckx B, Mazzone M, Zacchigna
S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M,
De MM, Autiero M, Wyns S, Plaisance S, Moons L, van RN, Giacca M,
Stassen JM, Dewerchin M, Collen D and Carmeliet P: Anti-PlGF
inhibits growth of VEGF(R)-inhibitor-resistant tumors without
affecting healthy vessels. Cell. 131:463–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Coenegrachts L, Maes C, Torrekens S, Van
LR, Mazzone M, Guise TA, Bouillon R, Stassen JM, Carmeliet P and
Carmeliet G: Anti-placental growth factor reduces bone metastasis
by blocking tumor cell engraftment and osteoclast differentiation.
Cancer Res. 70:6537–6547. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Van de Veire S, Stalmans I, Heindryckx F,
Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx
B, Vinckier S, Van SC, Tugues S, Rolny C, De MM, Dettori D, Hainaud
P, Coenegrachts L, Contreres JO, Van BT, Cuervo H, Xiao WH, Le HC,
Buysschaert I, Kharabi MB, Geerts A, Schomber T, Bonnin P, Lambert
V, Haustraete J, Zacchigna S, Rakic JM, Jimenez W, Noel A, Giacca
M, Colle I, Foidart JM, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell
P, Vinores SA, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E,
Van VH, Christofori G, Mazzone M, Detmar M, Collen D and Carmeliet
P: Further pharmacological and genetic evidence for the efficacy of
PlGF inhibition in cancer and eye disease. Cell. 141:178–190.
2010.PubMed/NCBI
|
|
14
|
Maae E, Olsen DA, Steffensen KD, Jakobsen
EH, Brandslund I, Sorensen FB and Jakobsen A: Prognostic impact of
placenta growth factor and vascular endothelial growth factor A in
patients with breast cancer. Breast Cancer Res Treat. 133:257–265.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Parr C, Watkins G, Boulton M, Cai J and
Jiang WG: Placenta growth factor is over-expressed and has
prognostic value in human breast cancer. Eur J Cancer.
41:2819–2827. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu
JJ, Wu CH, Su YN, Hsieh FJ and Wong JM: Placenta growth factor
expression is correlated with survival of patients with colorectal
cancer. Gut. 54:666–672. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sivridis E, Giatromanolaki A, Anastasiadis
P, Georgiou L, Gatter KC, Harris AL, Bicknell R and Koukourakis MI:
Angiogenic co-operation of VEGF and stromal cell TP in endometrial
carcinomas. J Pathol. 196:416–422. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luttun A, Tjwa M, Moons L, Wu Y,
Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De KB,
Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R,
Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ and
Carmeliet P: Revascularization of ischemic tissues by PlGF
treatment, and inhibition of tumor angiogenesis, arthritis and
atherosclerosis by anti-Flt1. Nat Med. 8:831–840. 2002.PubMed/NCBI
|
|
20
|
Koukourakis MI, Limberis V, Tentes I,
Kontomanolis E, Kortsaris A, Sivridis E and Giatromanolaki A: Serum
VEGF levels and tissue activation of VEGFR2/KDR receptors in
patients with breast and gynecologic cancer. Cytokine. 53:370–375.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang YT, Chang MC, Wei SC, Tien YW, Hsu
C, Liang PC, Tsao PN, Jan IS and Wong JM: Serum vascular
endothelial growth factor/soluble vascular endothelial growth
factor receptor 1 ratio is an independent prognostic marker in
pancreatic cancer. Pancreas. 37:145–150. 2008. View Article : Google Scholar
|
|
22
|
Pompeo E, Albonici L, Doldo E, Orlandi A,
Manzari V, Modesti A and Mineo TC: Placenta growth factor
expression has prognostic value in malignant pleural mesothelioma.
Ann Thorac Surg. 88:426–431. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wei SC, Liang JT, Tsao PN, Hsieh FJ, Yu SC
and Wong JM: Preoperative serum placenta growth factor level is a
prognostic biomarker in colorectal cancer. Dis Colon Rectum.
52:1630–1636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang L, Chen J, Ke Y, Mansel RE and Jiang
WG: Expression of placenta growth factor (PlGF) in non-small cell
lung cancer (NSCLC) and the clinical and prognostic significance.
World J Surg Oncol. 3:682005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su
YN, Chang KJ and Lee PH: The significance of placenta growth factor
in angiogenesis and clinical outcome of human gastric cancer.
Cancer Lett. 213:73–82. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Voss MA, Ganesan R, Ludeman L, McCarthy K,
Gornall R, Schaller G, Wei W and Sundar S: Should grade 3
endometrioid endometrial carcinoma be considered a type 2 cancer-A
clinical and pathological evaluation. Gynecol Oncol. 124:15–20.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martinsson-Niskanen T, Riisbro R, Larsson
L, Winstedt L, Stenberg Y, Pakola S, Stassen JM and Glazer S:
Monoclonal antibody TB-403: a first-in-human, Phase I,
double-blind, dose escalation study directed against placental
growth factor in healthy male subjects. Clin Ther. 33:1142–1149.
2011. View Article : Google Scholar
|
